| DC71531 |
ODN 1826 |
ODN 1826, a class B ODN (oligodeoxynucleotide), is a TLR9 agonist. CpG ODN 1826 is an excellent immunostimulator that induces NO and iNOS production in the murine model. CpG ODN 1826 enhances cell apoptosis. ODN 1826 sequence: 5’-tccatgacgttcctgacgtt-3’. |
|
| DC71786 |
ODN 2395 |
ODN 2395 is a C class oligodeoxynucleotide and can be used as vaccine adjuvant. ODN 2395 is also a TLR9 agonist. Sequence: 5'-tcgtcgttttcggcgc:gcgccg-3'. |
|
| DC71789 |
ODN D-SL01 |
ODN D-SL01, a class B CpG ODN (oligodeoxynucleotide), is a TLR9 agonist. ODN D-SL01 has strong immunostimulatory activity in a variety of vertebrate species and has anticancer activity. ODN D-SL01 sequence: 5'- T-C-G-C-G-A-C-G-T-T-C-G-C-C-C-G-A-C-G-T-T-C-G-G-T-A-3'. |
|
| DC67258 |
ODN 1018 |
ODN 1018 (1018 ISS), an oligodeoxynucleotide, is a TLR-9 agonist. ODN 1018 is also a synthetic immunostimulatory sequence that can be used as vaccine adjuvant. Sequence: 5′-TGACTGTGAACGTTCGAGATGA-3′.
The free form of the compound is prone to instability, it is advisable to consider the stable salt form (ODN 1018 sodium) that retains the same biological activity. |
|
| DC67259 |
ODN 2006 Sodium |
Agatolimod sodium (ODN 2006) is a class B CpG ODN and is a TLR9 agonist. Agatolimod sodium can be used as vaccine adjuvant. Agatolimod sodium can be used for the research of cancer. Sequence: 5’-TCGTCGTTTTGTCGTTTTGTCGTT-3’. |
|
| DC67261 |
ODN 2007 |
ODN 2007, a class B CpG ODN (oligodeoxynucleotide), is a Toll-like receptor (TLR) ligand. ODN 2007 can be used as an immunomodulator, vaccine adjuvant, and enhance immune responses in mammals, fish, and humans. ODN 2007 sequence: 5'-TCGTCGTTGTCGTTTTGTCGTT-3'.
The free form of the compound is prone to instability, it is advisable to consider the stable salt form (ODN 2007 sodium) that retains the same biological activity. |
|
| DC67260 |
ODN YW07 Sodium |
|
|
| DC67262 |
PD-ODN 2006×3 Sodium |
|
|
| DC67263 |
ODN D-SL03 |
ODN D-SL03 is a C class CpG oligonucleotides, can induce stimulate PBMCs to produce high level of IFN-α. ODN D-SL03 can activate human B cells, NK cells and mononuclear cells and up-regulate expression of CD80, CD86 and HLA-DR on the surface of subsets in human PBMCs. ODN D-SL03 also can inhibit the growth of the tumor. ODN D-SL03 sequence: 5'-tcgcgaacgttcgccgcgttcgaacgcgg-3'.
The free form of the compound is prone to instability, it is advisable to consider the stable salt form (ODN D-SL03 sodium) that retains the same biological activity. |
|
| DC67264 |
ODN SD-101 Sodium |
|
|
| DC67265 |
ODN 2336 |
ODN 2336 is a A-Class CpG ODN (oligodeoxynucleotides), is a potent TLR9 agonist. ODN 2336 induces the production of IFN-α. ODN 2336 up-regulates the expression of IP-10 mRNA and IL-18 mRNA. ODN 2336 can be used as adjuvant of vaccines.
The free form of the compound is prone to instability, it is advisable to consider the stable salt form (ODN 2336 sodium) that retains the same biological activity. |
|
| DC67266 |
ODN 2216 |
ODN?2216 is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN?2216 induces high amounts of IFN-α and IFN-β. ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4+ T cells.
The free form of the compound is prone to instability, it is advisable to consider the stable salt form (ODN 2216 sodium) that retains the same biological activity. |
|
| DC67267 |
CpG-ODN no.2 Sodium |
|
|
| DC67268 |
ODN 21798 Sodium |
|
|
| DC67269 |
INH ODN4348 Sodium |
|
|
| DC67270 |
INH ODN4347 Sodium |
|
|
| DC67271 |
ODN IH-18 Sodium |
|
|
| DC67272 |
INH ODNIRS-869 Sodium |
|
|
| DC67273 |
ODN INH-1 |
ODN INH-1 is palindromic and a class R (‘restricted’) inhibitory ODN. ODN INH-1 is a potent inhibitor of TLR9-induced B cells and macrophages |
|
